Statistics
Total Visits
Views | |
---|---|
The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial | 73 |
The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial | 37 |
Total Visits per Month
October 2023 | November 2023 | December 2023 | January 2024 | February 2024 | March 2024 | April 2024 | |
---|---|---|---|---|---|---|---|
The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial | 0 | 7 | 0 | 2 | 1 | 5 | 0 |
File Downloads
Views |
---|
Top Country Views
Views | |
---|---|
United States | 52 |
China | 18 |
Vietnam | 12 |
Netherlands | 9 |
Australia | 3 |
France | 2 |
Canada | 1 |
Germany | 1 |
Israel | 1 |
Top City Views
Views | |
---|---|
Ashburn | 16 |
Fairfield | 14 |
Hanoi | 12 |
Rotterdam | 8 |
New York | 6 |
Zhengzhou | 3 |
Cambridge | 2 |
Des Moines | 2 |
Adelaide | 1 |
Augusta | 1 |